AU2022298841A1 - Use of mazdutide - Google Patents

Use of mazdutide Download PDF

Info

Publication number
AU2022298841A1
AU2022298841A1 AU2022298841A AU2022298841A AU2022298841A1 AU 2022298841 A1 AU2022298841 A1 AU 2022298841A1 AU 2022298841 A AU2022298841 A AU 2022298841A AU 2022298841 A AU2022298841 A AU 2022298841A AU 2022298841 A1 AU2022298841 A1 AU 2022298841A1
Authority
AU
Australia
Prior art keywords
dose
uric acid
administered
medicament
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022298841A
Other languages
English (en)
Inventor
Pei An
Huan DENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of AU2022298841A1 publication Critical patent/AU2022298841A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2022298841A 2021-06-25 2022-06-23 Use of mazdutide Pending AU2022298841A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110711050.0 2021-06-25
CN202110711050 2021-06-25
PCT/CN2022/100878 WO2022268174A1 (zh) 2021-06-25 2022-06-23 Mazdutide的应用

Publications (1)

Publication Number Publication Date
AU2022298841A1 true AU2022298841A1 (en) 2024-01-25

Family

ID=84544128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022298841A Pending AU2022298841A1 (en) 2021-06-25 2022-06-23 Use of mazdutide

Country Status (9)

Country Link
US (1) US20240293513A1 (https=)
EP (1) EP4360641A4 (https=)
JP (1) JP2024524273A (https=)
KR (1) KR20240027053A (https=)
CN (1) CN117597135A (https=)
AU (1) AU2022298841A1 (https=)
CA (1) CA3224043A1 (https=)
TW (1) TW202300171A (https=)
WO (1) WO2022268174A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250021331A (ko) * 2022-06-01 2025-02-12 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 mazdutide를 사용하는 치료 방법
WO2025073289A1 (en) * 2023-10-03 2025-04-10 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
WO2025073288A1 (en) * 2023-10-03 2025-04-10 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating adolescent obesity
CN120676965A (zh) * 2023-11-07 2025-09-19 深圳信立泰药业股份有限公司 多重受体共激动剂化合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI700291B (zh) * 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
KR20250021331A (ko) * 2022-06-01 2025-02-12 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 mazdutide를 사용하는 치료 방법

Also Published As

Publication number Publication date
CN117597135A (zh) 2024-02-23
JP2024524273A (ja) 2024-07-05
US20240293513A1 (en) 2024-09-05
CA3224043A1 (en) 2022-12-29
EP4360641A4 (en) 2025-10-22
KR20240027053A (ko) 2024-02-29
EP4360641A1 (en) 2024-05-01
TW202300171A (zh) 2023-01-01
WO2022268174A1 (zh) 2022-12-29

Similar Documents

Publication Publication Date Title
US20240293513A1 (en) Use of mazdutide
EP2324853B1 (en) Lixisenatide as add-on to metformin in the treatment of diabetes type 2
US20110118180A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20250296973A1 (en) Treatment method using mazdutide
JP2003534289A (ja) Ｇｌｐ−１を用いた急性冠状動静脈症候群の治療
Simpson et al. Insulin aspart
AU2019229469B2 (en) GLP-1 composition for treating obesity and weight management
McFarlane Antidiabetic medications and weight gain: implications for the practicing physician
HK40110048A (en) Use of mazdutide
HK40118093A (en) Treatment method using mazdutide
WO2025073289A1 (en) Methods of treating diabetes and obesity
RU2834226C2 (ru) Композиция glp-1 для лечения ожирения и регулирования веса
AU2023281706A1 (en) Methods of using a gcg/glp1 co-agonist for therapy
Das et al. New Horizons in T2DM Management: A Review of Emerging Antidiabetic Medications
CA2685636C (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
TW202140061A (zh) 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
HK40013213A (en) Glp-1 composition for treating obesity and weight management
Sorbera et al. Insulin glulisine
AU2009238272A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
HK40056898A (en) Glp-1 composition for treating obesity and weight management
İMAMOĞLU BASIC ASPECTS OF ANTIDIABETIC DRUGS AND TREATMENT IN TYPE 2 DIABETES MELLITUS
JP2021528424A (ja) 対象における食後のグルコースレベルをコントロールする方法および使用
KR20110052987A (ko) 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법